You are viewing: China Immune Repertoire Sequencing Market analysis

The China Immune Repertoire Sequencing Market was valued at $20.3 Million in 2025 and projected to reach to $34.5 Million by 2030, representing a compound annual growth rate of 11.2%. China's immune repertoire sequencing market is poised for sustained growth driven by expanding precision medicine initiatives and increased R&D spending in immunotherapy.

China Immune Repertoire Sequencing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Immune Repertoire Sequencing Market Trends and Insights

  • This growth trajectory reflects China's increasing investment in precision medicine and immunological research infrastructure.
  • China is leveraging advanced sequencing technologies to enhance diagnostic capabilities and accelerate immunotherapy development across oncology and infectious disease applications. The market in China is driven by rising healthcare expenditure, growing adoption of next-generation sequencing platforms, and expanding clinical applications in personalized medicine.
  • China's regulatory environment is becoming increasingly supportive of genomic technologies, enabling faster market penetration.
  • By 2030, China is expected to solidify its position as a key regional hub for immune repertoire sequencing, supported by government initiatives and private sector innovation in biotechnology..

Key Market Statistics

  • CAGR (2025-2030) 11.2% CAGR
  • Market Size, 2025 ~USD 20.3 Million
  • Forecast, 2030 ~USD 34.5 Million
  • Country China

China Immune Repertoire Sequencing Market Overview

Market Valuation Growth :

China's immune repertoire sequencing market is valued at $20.3 million in 2025, with a projected CAGR of 11.2% through 2030, reaching $34.5 million. This outpaces the global CAGR of 9.6%, indicating China's accelerating adoption of advanced sequencing technologies.

Precision Medicine Investment :

China is significantly increasing government and private sector investments in precision medicine infrastructure, positioning immune repertoire sequencing as a critical diagnostic tool for personalized treatment strategies and immunotherapy development.

Immunotherapy Acceleration :

Chinese pharmaceutical and biotech companies are rapidly advancing immunotherapy programs, driving demand for immune repertoire sequencing to characterize T-cell and B-cell populations, optimize CAR-T therapies, and enhance clinical trial outcomes.

Sequencing Technology Adoption :

Major Chinese research institutions and hospitals are deploying next-generation sequencing platforms for immunological profiling, supported by declining sequencing costs and growing expertise in bioinformatics analysis and data interpretation.

China Immune Repertoire Sequencing Market Dynamics

  • Government support for biotechnology innovation, coupled with rising healthcare expenditures, creates favorable conditions for market expansion.
  • Chinese biotech firms are investing heavily in immune profiling capabilities to compete globally in immunotherapy development. The market will benefit from growing clinical applications in cancer immunotherapy, infectious disease diagnostics, and autoimmune disorder management.
  • Enhanced sequencing infrastructure, improved data analytics capabilities, and increasing collaboration between academic institutions and industry will further accelerate adoption.
  • By 2030, China is expected to establish itself as a significant hub for immune repertoire sequencing research and clinical applications..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • China's immune repertoire sequencing market is valued at $20.3 million in 2025 and will grow to $34.5 million by 2030, representing an 11.2% CAGR.
    • China is investing heavily in precision medicine infrastructure, driving adoption of advanced sequencing technologies for immunotherapy and personalized diagnostics.
    • Regulatory support and government initiatives in China are accelerating market growth and enabling faster commercialization of immune sequencing solutions.
    • China's expanding clinical applications in oncology and infectious disease are creating significant opportunities for immune repertoire sequencing market expansion through 2030.

    Immune Repertoire Sequencing Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment TCR KITS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.6% from 2025 to 2030
    Largest Segment ASSAY KITS & REAGENTS (Product)
    Market Size Base Year (Billions) ~USD 0.35 (2025)
    Revenue Forecast (Billions) ~USD 0.56 (2030)
    Segments Covered Product, Type

    China Immune Repertoire Sequencing Market Report Segmentation

    2 segment dimensions are covered across the global market.

    By Product

    • Assay Kits & Reagents
    • Instruments & Software

    By Type

    • Bcr Kits
    • Other Assay Kits & Reagents
    • Tcr Kits

    CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES9.19.310.311.412.61415.617.411.2
    OTHER END USERS5.55.66.16.77.48.291010.3
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES8.28.49.310.411.512.814.31611.4
    TOTAL22.823.325.728.531.635.13943.511

    CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES3.22.21.91.81.82.12.53.312
    OTHER END USERS1.81.31.1111.11.41.810.7
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES4.73.32.82.72.83.13.8512.1
    TOTAL9.76.85.85.45.66.37.710.111.8

    Target Audience

    • Biotech & Pharmaceutical Companies : Chinese and international biotech firms developing immunotherapies need detailed market insights to assess commercialization potential, identify clinical trial opportunities, and optimize immune profiling strategies for China's growing precision medicine market.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Chinese healthcare and biotechnology require accurate market sizing, growth projections, and competitive analysis to make informed funding decisions in the immune sequencing sector.
    • Diagnostic & Sequencing Companies : Manufacturers of sequencing platforms and diagnostic tools need China-specific market data to develop localized product strategies, identify distribution partnerships, and forecast revenue potential in this high-growth regional market.
    • Hospital & Research Institutions : Chinese academic medical centers and hospital networks require market intelligence to justify infrastructure investments, benchmark capabilities against peers, and develop immunology research programs aligned with national precision medicine initiatives.
    • Government & Policy Makers : Chinese healthcare policymakers and government agencies need comprehensive market analysis to inform precision medicine strategy development, funding allocation, and regulatory framework design for immune sequencing technologies.

    Key Companies in the China Immune Repertoire Sequencing Market

    CompanyHQOwnershipStrongest segments
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PACBIOUnited StatesPublic CompanyLong-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read sequencing (Onso and related consumables),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION (2/24/48) instruments and consumables,MinION Mk 1D and related consumables,GridION / GridION Q systems and consumables,
    10X GENOMICSUnited StatesPublic CompanyChromium single-cell instruments and consumables,Visium spatial instruments and consumables,Xenium in situ instruments and consumables,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious-disease diagnostics,Oncology and sexual & reproductive health assays,
    AGILENT TECHNOLOGIESUnited StatesPublic CompanyLife Sciences and Diagnostics (instruments, reagents, genomics, pathology, CDMO, biomolecular analysis),Agilent CrossLab (services, consumables, software, asset management),Applied Markets (GC, MS, spectroscopy, vacuum, remarketed instruments),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research and genomic tools),Diagnostics (clinical instruments and consumables),
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    ADAPTIVE BIOTECHNOLOGIESUnited StatesPublic CompanyclonoSEQ MRD diagnostics,Life sciences research immunosequencing,Pharma and biotech drug discovery partnerships,
    PERSONALIS, INC.United StatesPublic CompanyPharma and biotech translational research / clinical trial services (ImmunoID NeXT and exome-based services),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related tests),

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 that employs 8,625 people. The company operates in the life sciences and genomics sector.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. It is a major provider of analytical instruments, reagents, and laboratory services.

    PACBIO

    PacBio is a United States-based public company founded in 2000 with 485 employees. The company specializes in DNA sequencing technology and solutions.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees. It develops nanopore-based DNA and RNA sequencing technologies.

    10X GENOMICS

    10X Genomics is a United States-based public company founded in 2012 with 1,178 employees. The company provides solutions for single-cell and spatial genomics analysis.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It develops and manufactures molecular diagnostics and life sciences products.

    AGILENT TECHNOLOGIES

    Agilent Technologies is a United States-based public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. It operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company develops and manufactures molecular biology reagents and biotechnology products.

    ADAPTIVE BIOTECHNOLOGIES

    Adaptive Biotechnologies is a United States-based public company founded in 2009 with 624 employees. The company develops immune-driven diagnostics and therapeutics using T-cell and B-cell receptor sequencing.

    PERSONALIS, INC.

    Personalis, Inc. is a United States-based public company founded in 2011 with 260 employees. The company offers precision medicine and genomic analysis services.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for China ($20.3M in 2025) with verified 11.2% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
    • Competitive Landscape Intelligence : Understand China-specific competitive dynamics, key players, and market positioning strategies to identify partnership opportunities, acquisition targets, and differentiation strategies within the rapidly growing Chinese immune sequencing sector.
    • Regulatory & Infrastructure Insights : Access detailed analysis of China's regulatory environment, government initiatives, healthcare infrastructure development, and reimbursement policies affecting immune repertoire sequencing adoption and commercialization pathways.
    • Clinical Application Opportunities : Identify high-potential clinical applications in Chinese healthcare settings including cancer immunotherapy, infectious disease diagnostics, and autoimmune disorders, with market penetration strategies tailored to regional healthcare systems.
    • Strategic Growth Planning : Leverage China-specific market trends, technology adoption patterns, and investment forecasts to develop targeted go-to-market strategies, resource allocation plans, and long-term business development roadmaps for the Chinese market.

    Frequently asked questions

    What is the current market size of immune repertoire sequencing in China?

    China's immune repertoire sequencing market was valued at $20.3 million in 2025 and is projected to reach $34.5 million by 2030.

    What is the growth rate of the immune repertoire sequencing market in China?

    China's immune repertoire sequencing market is growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2030.

    What are the primary drivers of growth in China's immune repertoire sequencing market?

    Key drivers include rising healthcare expenditure, increased adoption of next-generation sequencing platforms, expanding clinical applications in personalized medicine, and supportive regulatory policies in China.

    Which applications are driving demand for immune repertoire sequencing in China?

    Primary applications in China include oncology immunotherapy, infectious disease diagnostics, and personalized medicine development, with growing adoption across academic and clinical research institutions.

    How is China's regulatory environment supporting immune repertoire sequencing market growth?

    China's regulatory framework is becoming increasingly supportive of genomic technologies, enabling faster market penetration and commercialization of immune sequencing solutions through streamlined approval processes.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    The following is a breakdown of the primary respondents:

    Immune Repertoire Sequencing Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.

    • The research methodology used to estimate the market size includes the following:
    • The key players in the immune repertoire sequencing market have been identified through extensive primary and secondary research.
    • The revenues generated from the immune repertoire sequencing businesses of leading players in product and service offerings were determined separately through primary and secondary research.
    • The sum of the product and service market was used to arrive at the total IRS global market size, which was further segmented into various segments.
    • All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.  
    Immune Repertoire Sequencing Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

    Market Definition

    Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.

    This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.

    Stakeholders

    • CDMOs & CROs
    • Pharmaceutical & Biopharmaceutical Companies
    • Academic & Research Institutes
    • Diagnostic Companies
    • Venture Capitalists & Investors
    • Market Research & Consulting Firms
    • Government & Regulatory Associations

    Report Objectives

    • To define, describe, and forecast the IRS market based on product, products technology, service workflow, application, product end user, service end user, and region.
    • To provide detailed information regarding the major factors influencing market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
    • To strategically analyze micromarkets concerning their growth trends, prospects, and contributions to the total IRS market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the revenue of market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
    • To profile key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments in the IRS market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities
    • To track and analyze the impact of AI/Gen AI on the IRS market
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and service excellence strategy

     

    Get the Full Immune Repertoire Sequencing Market Report

    Full forecast, segment splits, and company analysis for all Immune Repertoire Sequencing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status